2. Apoptosis
  3. Apoptosis
  4. Tigatuzumab

Tigatuzumab  (Synonyms: CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody)

Cat. No.: HY-P99270 Purity: 95.00%
COA

Molarity Calculator

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.

For research use only. We do not sell to patients.

Tigatuzumab Chemical Structure

Tigatuzumab Chemical Structure

CAS No. : 918127-53-4

Size Price Stock Quantity
1 mg USD 350 In-stock
5 mg USD 910 In-stock
10 mg USD 1500 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tigatuzumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

In Vitro

Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 and 8.21 μg/mL, respectively[1].
Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tigatuzumab Related Antibodies

Apoptosis Analysis[1]

Cell Line: MIA PaCa-2 and BxPC-3 cell lines
Concentration: 3 and 8 μg/mL
Incubation Time: 5 hours
Result: Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.
In Vivo

Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1]
Dosage: 3 mg/kg
Administration: Intravenous injection; 3 mg/kg weekly for 4 weeks
Result: Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
Clinical Trial
Molecular Weight

144.6 (kDa)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tigatuzumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 95.00%

COA (232 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tigatuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tigatuzumab918127-53-4CS-1008 Anti-Human TRAIL-R2 Recombinant AntibodyCS1008CS 1008Apoptosismonoclonal antibodyapoptosisanti-tumorcancermethionine restrictionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tigatuzumab
Cat. No.:
HY-P99270
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.